CAMP4 Therapeutics
CAMP
CAMP4 Therapeutics (CAMP) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Piper Sandler | Maintained | Overweight | $15.00 from $12.00 | Aug 14, 2026 |
| JP Morgan | Upgraded | Neutral → Overweight | $9.00 from $5.00 | Jun 16, 2026 |
| Chardan Capital | Initiated Coverage | Buy | $6.50 | Jun 10, 2026 |
| Rodman & Renshaw | Initiated Coverage | Buy | $7.00 | Apr 14, 2026 |
| Leerink Partners | Maintained | Outperform | $9.00 from $8.00 | Apr 2, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $7.00 | Oct 2, 2025 |
| JP Morgan | Downgraded | Overweight → Neutral | — | Sep 16, 2025 |
| Piper Sandler | Maintained | Overweight | $12.00 from $18.00 | Sep 15, 2025 |
| Wedbush | Initiated Coverage | Outperform | $8.00 | May 27, 2025 |
| JP Morgan | Initiated Coverage | Overweight | $23.00 | Nov 5, 2024 |
| Leerink Partners | Initiated Coverage | Outperform | $17.00 | Nov 5, 2024 |
| Piper Sandler | Initiated Coverage | Overweight | $18.00 | Nov 5, 2024 |
| William Blair | Initiated Coverage | Outperform | — | Nov 5, 2024 |
Frequently asked questions
What is the latest analyst rating on CAMP?
On Aug 14, 2026, Piper Sandler maintained CAMP4 Therapeutics at Overweight with a price target of $15.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.